Thus, glioblastoma organoids were found to be sensitive to gefitinib in EGFR mutation presence; to trametinib, in tumors with NF1 mutation, to everolimus, in tumors with PI3K mutation [96]. This evidence concerns the gene EGFR and glioblastoma.